• Recruiting

NCT04513639: Phase 2/3: The Relapse From MRD Negativity as Indication for Treatment (REMNANT) Study

Updated: May 25

NCT04513639: Phase 2/3: The Relapse From MRD Negativity as Indication for Treatment (REMNANT) Study


Dara-Kd

REMNANT Study Dara-Kd-MRD-Norway-Oslo

The Relapse From MRD Negativity as Indication for Treatment (REMNANT) Study


The REMNANT study will evaluate whether treating minimal residual disease (MRD) relapse after first line treatment prolongs progression free survival and overall survival for myeloma patients versus treating relapse after first line treatment at progressive disease. To establish a homogenous group of MRD negative patients after first line treatment including autologous stem cell transplantation, patients are enrolled at diagnosis and treated with Norwegian standard of care first line treatment. MRD negative patients will move on to the randomized part.


Sponsor:

Oslo University Hospital


Collaborators:

St. Olavs Hospital

Haukeland University Hospital

University Hospital of North Norway

University Hospital, Akershus

Helse Stavanger HF

Førde Central Hospital

Sorlandet Hospital HF

Nordlandssykehuset HF

The Hospital of Vestfold

Helse Nord-Trøndelag HF

Alesund Hospital

Sykehuset Ostfold

 

ClinicalTrials.gov Identifier: NCT04513639

Official Title: The Relapse From MRD Negativity as Indication for Treatment (REMNANT) Study

First Posted : August 14, 2020

Click here for details on Clinicaltrials.gov

 

Drug: Early treatment of relapse with carfilzomib, dexamethasone, daratumumab

Drug: Standard treatment of relapse with carfilzomib, dexamethasone, daratumumab

 

Location

Europe

Norway

Posts Archive